Medications information








Alosa Foundation Balanced Information for Better Care

10/20/2014
05:33 | Author: Steven Lewis

Medications information
Alosa Foundation Balanced Information for Better Care

Clinical modules from Alosa's Independent Drug Information Service (IDIS) Acid suppression Antipsychotic medications in nursing homes · COPD and.

Clinical modules from Alosa's Independent Drug Information Service (IDIS) Acid suppression Alzheimer's Disease and related disorders Antiplaet therapy Antipsychotic medications Antipsychotic medications in nursing homes COPD and smoking cessation Congestive heart failure Falls and mobility HIV/AIDS Obesity Type 2 diabetes.

Our clinical information is developed by research physicians and clinicians who have no personal financial relationships with any drug or device maker. is a 501(3) nonprofit organization which is not affiliated with any pharmaceutical company. The Alosa Foundation, Inc.

Alosa has also expanded its partnership with the Massachusetts Department of Public Health to not only use academic detailing as a means of educating providers on antipsychotic medications in nursing homes, but also to address the judicious prescribing of opioids in the community. Prescriber visits for this new program will commence in fall of 2014.

Read more about our educational materials →

Contact us.

Program Updates The Alosa Foundation has renewed its partnership with the HIV/AIDS, Hepatitis, STD and TB Administration (HAHSTA), of the District of Columbia Department of Health, to utilize academic detailing techniques in educating healthcare professionals about disease-specific health screenings.

Read more about our programs→

Comments (0)



Drug Shortages - ASHP

12/19/2014
03:06 | Author: Allison King

Medications information
Drug Shortages - ASHP

Welcome to the ASHP Drug Shortages Resource Center, the first stop for information and resources on drug product shortages and management.

Drug shortage bulletin development funding provided courtesy of Novation, LLC. Drug shortage bulletin content is developed by the University of Utah Drug Information Service.

ASHP is the national professional organization whose more than 40,000 members include pharmacists, student pharmacists, and pharmacy technicians who serve as patient care providers on healthcare teams in acute and ambulatory settings.

Understanding and Managing Drug Product Shortages More resources.

ASHP and its partners work to keep the public informed of the most current drug shortages. Welcome to the ASHP Drug Shortages Resource Center, the first stop for information and resources on drug product shortages and management. Drug shortages can adversely affect drug therapy, compromise or delay medical procedures, and result in medication errors.

Conservation Strategies for IV Fluids.

ASHP Guidance for Purchasing Drug Products in Short Supply.

ASHP Guidelines on Managing Drug Product Shortages.

Comments (0)

NAMI About Medications

10/18/2014
01:41 | Author: Steven Lewis

Medications information
NAMI About Medications

General Information about Specific Medications. Research is constantly providing us with new information about the brain and the nature of mental illness and.

Often, multiple types of medications must be assessed in order to find the one, or ones, that are the most effective for an individual. Not everyone responds to medications in the same way. Research is constantly providing us with new information about the brain and the nature of mental illness and, consequently, more effective treatments, including medications.

username: password:

Comments (0)

New FDA Approved Drugs for 2014 CenterWatch

8/17/2014
01:08 | Author: Jeremy Rodriguez

Medications information
New FDA Approved Drugs for 2014 CenterWatch

The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically.

Entyvio (vedolizumab) ; Millenium Pharmaceuticals; For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014.

Imbruvica (ibrutinib) ; Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014.

Ragwitek (Short Ragweed Pollen Allergen Extract) ; Merck; For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014.

Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals; For the treatment of acute bacterial skin and skin structure infections, Approved June 2014.

Qudexy XR (topiramate) ; Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014.

Afrezza (insulin human) Inhalation Powder ; Mannkind; For the treatment of diabetes mellitus, Approved June 2014.

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) ; Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014.

Otezla (apremilast) ; Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014.

Zydelig (idelalisib) ; Gilead; For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014.

Grastek (Timothy Grass Pollen Allergen Extract) ; Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014.

Kerydin (tavaborole) ; Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014.

Trulicity (dulaglutide) ; Eli Lilly; To improve glycemic control in type II diabetics, Approved September 2014.

Grastek (Timothy Grass Pollen Allergen Extract) ; Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014.

Zydelig (idelalisib) ; Gilead; For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014.

Entyvio (vedolizumab) ; Millenium Pharmaceuticals; For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014.

Arnuity Ellipta (fluticasone furoate inhalation powder) ; GlaxoSmithKline; For the treatment of asthma, Approved August 2014.

Myalept (metreleptin for injection) ; Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014.

Vimizim (elosulfase alfa) ; BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014.

Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] ; Biogen Idec; For the treatment of hemophilia B, Approved March 2014.

Ragwitek (Short Ragweed Pollen Allergen Extract) ; Merck; For the treatment of short ragweed pollen-induced allergic rhinitis, Approved April 2014.

Sylvant (siltuximab) ; Janssen Biotech; For the treatment of multicentric Castleman’s disease, Approved April 2014.

Drug Pipeline Resources Access the latest pipeline news from our industry-leading publications— The CenterWatch Monthly and CWWeekly.

Tivorbex (indomethacin) ; Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014.

Aveed (testosterone undecanoate) injection ; Endo Pharmaceuticals; For the treatment of hypogonadism, Approved March 2014.

Qudexy XR (topiramate) ; Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014.

Plegridy (peginterferon beta-1a) ; Biogen IDEC.; For the treatment of relapsing multiple sclerosis, Approved August 2014.

Hetlioz (tasimelteon) ; Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014.

Jardiance (empagliflozin) ; Boehringer Ingelheim; For the treatment of type II diabetes, Approved August 2014.

Entyvio (vedolizumab) ; Millenium Pharmaceuticals; For the treatment of adults with ulcerative colitis and Crohn's disease, Approved May of 2014.

Cyramza (ramucirumab) ; Eli Lilly; For the treatment of gastric cancer, Approved April 2014.

Otezla (apremilast) ; Celgene; For the treatment of moderate to severe plaque psoriasis, Approved September 2014.

Qudexy XR (topiramate) ; Upsher-Smith Laboratories; For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome, Approved March 2014.

Bunavail (buprenorphine and naloxone) ; BioDelivery Sciences; For the maintenance treatment of opioid dependence, Approved June 2014.

View By: Year Company Conditions Therapeutic Areas Drug Names.

Keytruda (pembrolizumab) ; Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014.

Farxiga (dapagliflozin) ; Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014.

Grastek (Timothy Grass Pollen Allergen Extract) ; Merck; For the treatment of grass pollen-induced allergic rhinitis, Approved April 2014.

Incruse Ellipta (umeclidinium inhalation powder) ; GlaxoSmithKline; For the treatment of chronic obstructive pulmonary disease, Approved May 2014.

Post Clinical Trials An international listing service of actively enrolling clinical trials to support sponsors and CROs in their patient enrollment initiatives.

Request a free demo.

Comments (4)Read more

Resources - Drug Disposal Information

6/16/2014
03:05 | Author: Molly Young

Medications information
Resources - Drug Disposal Information

DEA Registrant Drug Disposal. Letter to Registrants seeks to clarify the DEA position regarding a practitioner's disposal of pharmaceutical wastage (October 17.

Drug and Chemical Information E-commerce Initiatives.

HOME CONTACT US A-Z SUBJECT INDEX PRIVACY NOTICE WEBSITE ASSISTANCE REGISTRATION.

EPA – Disposal of Medical Sharps.

Got Drugs? - National Prescription Drug Take-Back Day.

Notice of Proposed Rulemaking (NPRM) NPRM Comments.

FDA – How to Dispose of Unused Medicines (PDF).

ARCOS BCM Online Chemical Import/Export Declarations CSOS (Controlled Substances Ordering System) Drug Theft/Loss Import/Export Inventory of Drugs Surrendered Quotas Reports Required by 21 CFR Submit a Tip to DEA Year-End Reports RESOURCES.

Title 21 USC Codified CSA.

EPA – How to Dispose of Medicines Properly (PDF).

FDA – Disposal of Unused Medicines.

Letter to Registrants regarding Disposal of Controlled Substances; Final Rule (PDF) (September 9, 2014).

Applications, Tools & Resources CMEA Required Training & Self-Certification Quota Applications ABOUT US.

DEPARTMENT OF JUSTICE • DRUG ENFORCEMENT ADMINISTRATION Office of Diversion Control • 8701 Morrissette Drive • Springfield, VA 22152 •.

Comments (5)Read more